Company profile OLMA
There is not enough data for women's cancers therapies to provide analysis
There is not enough data for women's cancers therapies to provide correlation calculation
There is not enough data for women's cancers therapies to provide analysis
There is not enough data for OP-1250 clinical trial to provide analysis
There is not enough data for OP-1250 clinical trial to provide correlation calculation
There is not enough data for OP-1250 clinical trial to provide analysis
There is not enough data for estrogen receptor antagonist to provide analysis
There is not enough data for estrogen receptor antagonist to provide correlation calculation
There is not enough data for estrogen receptor antagonist to provide analysis
There is not enough data for ER degrader to provide analysis
There is not enough data for ER degrader to provide correlation calculation
There is not enough data for ER degrader to provide analysis
There is not enough data for recurrent breast cancer treatment to provide analysis
There is not enough data for recurrent breast cancer treatment to provide correlation calculation
There is not enough data for recurrent breast cancer treatment to provide analysis
There is not enough data for locally advanced breast cancer treatment to provide analysis
There is not enough data for locally advanced breast cancer treatment to provide correlation calculation
There is not enough data for locally advanced breast cancer treatment to provide analysis
After 38 days of this quarter the interest is at 163.0. Based on that we can calculate that during remaining 53 days it will total up to 390.0. That appears to be equal to previous quarter and same quarter last year.
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 295 | 310 5.1% QoQ | 531 71.3% QoQ | 410 -22.8% QoQ |
| 2020 | 375 27.1% YoY -8.5% QoQ | 391 26.1% YoY 4.3% QoQ | 506 -4.7% YoY 29.4% QoQ | 415 1.2% YoY -18.0% QoQ |
| 2021 | 445 18.7% YoY 7.2% QoQ | 493 26.1% YoY 10.8% QoQ | 543 7.3% YoY 10.1% QoQ | 489 17.8% YoY -9.9% QoQ |
| 2022 | 475 6.7% YoY -2.9% QoQ | 347 -29.6% YoY -26.9% QoQ | 419 -22.8% YoY 20.7% QoQ | 298 -39.1% YoY -28.9% QoQ |
| 2023 | 386 -18.7% YoY 29.5% QoQ | 414 19.3% YoY 7.3% QoQ | 459 9.5% YoY 10.9% QoQ | 562 88.6% YoY 22.4% QoQ |
| 2024 | 163 -57.8% YoY -71.0% QoQ | - | - | - |
The average 5 years interest of metastatic breast cancer treatment was 33.56 per week. The last year interest of metastatic breast cancer treatment compared to the last 5 years has changed by 3.19%. The interest for metastatic breast cancer treatment is seasonal. The last year interest is comparable to 5 years ago. It has changed only by 7.25%.
There is not enough data for CDK4/6 inhibitors combination to provide analysis
There is not enough data for CDK4/6 inhibitors combination to provide correlation calculation
There is not enough data for CDK4/6 inhibitors combination to provide analysis
After 38 days of this quarter the interest is at 215.0. Based on that we can calculate that during remaining 53 days it will total up to 515.0. That appears to be equal to previous quarter and same quarter last year.
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 509 | 688 35.2% QoQ | 683 -0.7% QoQ | 747 9.4% QoQ |
| 2020 | 727 42.8% YoY -2.7% QoQ | 733 6.5% YoY 0.8% QoQ | 603 -11.7% YoY -17.7% QoQ | 536 -28.2% YoY -11.1% QoQ |
| 2021 | 615 -15.4% YoY 14.7% QoQ | 644 -12.1% YoY 4.7% QoQ | 545 -9.6% YoY -15.4% QoQ | 612 14.2% YoY 12.3% QoQ |
| 2022 | 709 15.3% YoY 15.8% QoQ | 642 -0.3% YoY -9.4% QoQ | 678 24.4% YoY 5.6% QoQ | 656 7.2% YoY -3.2% QoQ |
| 2023 | 674 -4.9% YoY 2.7% QoQ | 469 -26.9% YoY -30.4% QoQ | 579 -14.6% YoY 23.5% QoQ | 520 -20.7% YoY -10.2% QoQ |
| 2024 | 215 -68.1% YoY -58.7% QoQ | - | - | - |
The average 5 years interest of palbociclib was 49.17 per week. The last year interest of palbociclib compared to the last 5 years has changed by -14.5%. The interest for palbociclib is seasonal. The last year interest is quite lower compared to 5 years ago. It has decreased by -26.22%.
After 38 days of this quarter the interest is at 64.0. Based on that we can calculate that during remaining 53 days it will total up to 153.0. ribociclib expected interest is significantly lower compared to previous quarter (-48.1%) and same quarter last year (-40.9%).
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 83 | 256 208.4% QoQ | 176 -31.2% QoQ | 134 -23.9% QoQ |
| 2020 | 207 149.4% YoY 54.5% QoQ | 117 -54.3% YoY -43.5% QoQ | 130 -26.1% YoY 11.1% QoQ | 114 -14.9% YoY -12.3% QoQ |
| 2021 | 85 -58.9% YoY -25.4% QoQ | 112 -4.3% YoY 31.8% QoQ | 94 -27.7% YoY -16.1% QoQ | 115 0.9% YoY 22.3% QoQ |
| 2022 | 201 136.5% YoY 74.8% QoQ | 171 52.7% YoY -14.9% QoQ | 180 91.5% YoY 5.3% QoQ | 210 82.6% YoY 16.7% QoQ |
| 2023 | 259 28.9% YoY 23.3% QoQ | 328 91.8% YoY 26.6% QoQ | 331 83.9% YoY 0.9% QoQ | 295 40.5% YoY -10.9% QoQ |
| 2024 | 64 -75.3% YoY -78.3% QoQ | - | - | - |
The average 5 years interest of ribociclib was 14.08 per week. The last year interest of ribociclib compared to the last 5 years has changed by 60.23%. This is something to be checked. The last year interest is quite higher compared to 5 years ago. It has increased by 59.77%.
After 38 days of this quarter the interest is at 151.0. Based on that we can calculate that during remaining 53 days it will total up to 362.0. That appears to be equal to previous quarter and same quarter last year.
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 99 | 454 358.6% QoQ | 573 26.2% QoQ | 535 -6.6% QoQ |
| 2020 | 538 443.4% YoY 0.6% QoQ | 403 -11.2% YoY -25.1% QoQ | 423 -26.2% YoY 5.0% QoQ | 281 -47.5% YoY -33.6% QoQ |
| 2021 | 187 -65.2% YoY -33.5% QoQ | 404 0.2% YoY 116.0% QoQ | 134 -68.3% YoY -66.8% QoQ | 286 1.8% YoY 113.4% QoQ |
| 2022 | 373 99.5% YoY 30.4% QoQ | 498 23.3% YoY 33.5% QoQ | 360 168.7% YoY -27.7% QoQ | 438 53.1% YoY 21.7% QoQ |
| 2023 | 426 14.2% YoY -2.7% QoQ | 444 -10.8% YoY 4.2% QoQ | 442 22.8% YoY -0.5% QoQ | 431 -1.6% YoY -2.5% QoQ |
| 2024 | 151 -64.6% YoY -65.0% QoQ | - | - | - |
The average 5 years interest of alpelisib was 30.31 per week. The last year interest of alpelisib compared to the last 5 years has changed by 6.83%. The interest for alpelisib is seasonal. The last year interest is comparable to 5 years ago. It has changed only by -12.58%.
There is not enough data for CombiThera to provide analysis
There is not enough data for CombiThera to provide correlation calculation
There is not enough data for CombiThera to provide analysis
There is not enough data for Olema Pharmaceuticals corporate governance to provide analysis
There is not enough data for Olema Pharmaceuticals corporate governance to provide correlation calculation
There is not enough data for Olema Pharmaceuticals corporate governance to provide analysis